This web app has an overview on Regulatory science and Drug development tools (DDTs), in different stages of their development and based on information made publicly available by the EMA and FDA. Developers of such tools include academia, public-private consortia and for-profit entities. Public information on the stage of research and development of these tools and methodologies serves the broader community of developers and researchers to use the tools for their activities and may lead to investigate expanding their use. The publications listed below further explain the processes, impact and selected cases. The collaborative development of drug development and related tools is also addressed in reports and a guide by the Innovative Health Initiative (IHI), a flagship public-private partnerships of the EU, as well as a previous catalogue of project tools.
5011 {5011:8AZBTTLR},{5011:TQ942CQI},{5011:PC4UQJKL} 1 chicago-author-date 50 default 15163 https://paediatricdata.eu/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22PC4UQJKL%22%2C%22library%22%3A%7B%22id%22%3A5011%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Stephenson%20et%20al.%22%2C%22parsedDate%22%3A%222019-07-30%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3EStephenson%2C%20Diane%2C%20Derek%20Hill%2C%20Jesse%20M.%20Cedarbaum%2C%20Maria%20Tome%2C%20Spiros%20Vamvakas%2C%20Klaus%20Romero%2C%20Daniela%20J.%20Conrado%2C%20et%20al.%202019.%20%26%23x201C%3BThe%20Qualification%20of%20an%20Enrichment%20Biomarker%20for%20Clinical%20Trials%20Targeting%20Early%20Stages%20of%20Parkinson%26%23x2019%3Bs%20Disease.%26%23x201D%3B%20%3Ci%3EJournal%20of%20Parkinson%26%23x2019%3Bs%20Disease%3C%5C%2Fi%3E%209%20%283%29%3A%20553%26%23x2013%3B63.%20%3Ca%20class%3D%27zp-ItemURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3233%5C%2FJPD-191648%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3233%5C%2FJPD-191648%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Qualification%20of%20an%20Enrichment%20Biomarker%20for%20Clinical%20Trials%20Targeting%20Early%20Stages%20of%20Parkinson%5Cu2019s%20Disease%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Diane%22%2C%22lastName%22%3A%22Stephenson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Derek%22%2C%22lastName%22%3A%22Hill%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jesse%20M.%22%2C%22lastName%22%3A%22Cedarbaum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Tome%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Spiros%22%2C%22lastName%22%3A%22Vamvakas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Klaus%22%2C%22lastName%22%3A%22Romero%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Daniela%20J.%22%2C%22lastName%22%3A%22Conrado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20T.%22%2C%22lastName%22%3A%22Dexter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22John%22%2C%22lastName%22%3A%22Seibyl%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Danna%22%2C%22lastName%22%3A%22Jennings%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Timothy%22%2C%22lastName%22%3A%22Nicholas%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dawn%22%2C%22lastName%22%3A%22Matthews%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhiyong%22%2C%22lastName%22%3A%22Xie%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Syed%22%2C%22lastName%22%3A%22Imam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Paul%22%2C%22lastName%22%3A%22Maguire%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%22%2C%22lastName%22%3A%22Russell%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%20Forrest%22%2C%22lastName%22%3A%22Gordon%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Glenn%20T.%22%2C%22lastName%22%3A%22Stebbins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ed%22%2C%22lastName%22%3A%22Somer%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jill%22%2C%22lastName%22%3A%22Gallagher%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Arthur%22%2C%22lastName%22%3A%22Roach%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Peter%22%2C%22lastName%22%3A%22Basseches%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Donald%22%2C%22lastName%22%3A%22Grosset%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kenneth%22%2C%22lastName%22%3A%22Marek%22%7D%5D%2C%22abstractNote%22%3A%22As%20therapeutic%20trials%20target%20early%20stages%20of%20Parkinson%5Cu2019s%20disease%20%28PD%29%2C%20appropriate%20patient%20selection%20based%20purely%20on%20clinical%20criteria%20poses%20significant%20challenges.%20Members%20of%20the%20Critical%20Path%20for%20Parkinson%5Cu2019s%20Consortium%20formally%20submitted%20documentation%20to%20the%20European%20Medicines%20Agency%20%28EMA%29%20supporting%20the%20use%20of%20Dopamine%20Transporter%20%28DAT%29%20neuroimaging%20in%20early%20PD.%20Regulatory%20documents%20included%20a%20comprehensive%20literature%20review%2C%20a%20proposed%20analysis%20plan%20of%20both%20observational%20and%20clinical%20trial%20data%2C%20and%20an%20assessment%20of%20biomarker%20reproducibility%20and%20reliability.%20The%20research%20plan%20included%20longitudinal%20analysis%20of%20the%20Parkinson%20Research%20Examination%20of%20CEP-1347%20Trial%20%28PRECEPT%29%20and%20the%20Parkinson%5Cu2019s%20Progression%20Markers%20Initiative%20%28PPMI%29%20study%20to%20estimate%20the%20degree%20of%20enrichment%20achieved%20and%20impact%20on%20future%20trials%20in%20subjects%20with%20early%20motor%20PD.%20The%20presence%20of%20reduced%20striatal%20DAT%20binding%20based%20on%20visual%20reads%20of%20single%20photon%20emission%20tomography%20%28SPECT%29%20scans%20in%20early%20motor%20PD%20subjects%20was%20an%20independent%20predictor%20of%20faster%20decline%20in%20UPDRS%20Parts%20II%20and%20III%20as%20compared%20to%20subjects%20with%20scans%20without%20evidence%20of%20dopaminergic%20deficit%20%28SWEDD%29%20over%2024%20months.%20The%20EMA%20issued%20in%202018%20a%20full%20Qualification%20Opinion%20for%20the%20use%20of%20DAT%20as%20an%20enrichment%20biomarker%20in%20PD%20trials%20targeting%20subjects%20with%20early%20motor%20symptoms.%20Exclusion%20of%20SWEDD%20subjects%20in%20future%20clinical%20trials%20targeting%20early%20motor%20PD%20subjects%20aims%20to%20enrich%20clinical%20trial%20populations%20with%20idiopathic%20PD%20patients%2C%20improve%20statistical%20power%2C%20and%20exclude%20subjects%20who%20are%20unlikely%20to%20progress%20clinically%20from%20being%20exposed%20to%20novel%20test%20therapeutics.%22%2C%22date%22%3A%222019-07-30%22%2C%22language%22%3A%22EN%22%2C%22DOI%22%3A%2210.3233%5C%2FJPD-191648%22%2C%22ISSN%22%3A%221877-7171%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3233%5C%2FJPD-191648%22%2C%22collections%22%3A%5B%226PHBCNM8%22%5D%2C%22dateModified%22%3A%222025-05-21T05%3A56%3A01Z%22%7D%7D%2C%7B%22key%22%3A%22TQ942CQI%22%2C%22library%22%3A%7B%22id%22%3A5011%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Silva%20et%20al.%22%2C%22parsedDate%22%3A%222023-09-11%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ESilva%2C%20Marcio%2C%20Jane%20Moseley%2C%20Thorsten%20Vetter%2C%20Jan%20Regnstrom%2C%20Maria%20Tome%2C%20Stiina%20Aarum%2C%20Francesca%20Cerreta%2C%20Elmer%20Schabel%2C%20and%20Spiros%20Vamvakas.%202023.%20%26%23x201C%3BPatient-Reported%2C%20Observer-Reported%20and%20Performance%20Outcomes%20in%20Qualification%20Procedures%20at%20the%20European%20Medicines%20Agency%20%28EMA%29%202013-2018.%26%23x201D%3B%20%3Ci%3EBritish%20Journal%20of%20Clinical%20Pharmacology%3C%5C%2Fi%3E%2090%20%281%29%3A%20299%26%23x2013%3B312.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbcp.15907%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fbcp.15907%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Patient-reported%2C%20observer-reported%20and%20performance%20outcomes%20in%20qualification%20procedures%20at%20the%20European%20Medicines%20Agency%20%28EMA%29%202013-2018%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Marcio%22%2C%22lastName%22%3A%22Silva%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jane%22%2C%22lastName%22%3A%22Moseley%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Thorsten%22%2C%22lastName%22%3A%22Vetter%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jan%22%2C%22lastName%22%3A%22Regnstrom%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maria%22%2C%22lastName%22%3A%22Tome%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Stiina%22%2C%22lastName%22%3A%22Aarum%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francesca%22%2C%22lastName%22%3A%22Cerreta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Elmer%22%2C%22lastName%22%3A%22Schabel%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Spiros%22%2C%22lastName%22%3A%22Vamvakas%22%7D%5D%2C%22abstractNote%22%3A%22We%20analysed%20the%20regulatory%20output%20of%20EMA%20Qualification%20Procedures%20on%20patient-reported%20outcomes%20%28PROs%29%2C%20observer-reported%20outcomes%20%28ObsROs%29%20and%20performance%20outcomes%20%28PerfOs%29%20finalised%20between%20January%202013%20and%20December%202018%20to%20describe%20the%20tools%2C%20target%20populations%2C%20therapeutic%20areas%2C%20types%20of%20questions%2C%20endpoint%20role%20and%20the%20responses%20of%20EU%20regulators.%20We%20distilled%20general%20learnings%20from%20the%20procedures.%20Seventeen%20qualification%20programs%20for%20PROs%2C%206%20for%20ObsRO%20tools%20and%2011%20for%20PerfO%20tools%20were%20submitted%20by%20consortia%2C%20large%20and%20small%5C%2Fmedium%20companies.%20Gastroenterology%20and%20neurology%20were%20the%20most%20frequent%20therapeutic%20areas.%20There%20was%20a%20high%20level%20of%20regulators%5Cu2019%20partial%20agreement%20%28above%2070%25%29%20with%20applicant%5Cu2019s%20approaches%20with%20constructive%20input%3B%20EMA%20published%20Letters%20of%20Support%20for%20PRO%20%286%29%2C%20ObsRO%20%282%29%20and%20PerfO%20%284%29%20tools%2C%20and%20qualification%20opinions%20on%20PROs%20%282%29%2C%20and%20PerfOs%20%281%29.%20The%20most%20frequent%20general%20issues%20related%20to%20Qualification%20Procedures%20on%20PROs%20raised%20by%20EU%20regulators%20related%20to%20population%2C%20appropriate%20studies%20to%20demonstrate%20ability%20to%20detect%20change%2C%20tool%20validation%20in%20interventional%20trials%2C%20anchoring%2C%20identification%20of%20the%20minimally%20important%20difference%2C%20item%20selection%2C%20weighting%2C%20multiple%20domains%2C%20and%20use%20of%20PROs%5Cu2019%20subdomains%20as%20clinical%20endpoints.%20In%20addition%2C%20specific%20issues%20for%20ObsROs%20and%20PerfO%20tools%20validation%20are%20identified.%20Overall%2C%20a%20need%20to%20discuss%20principles%20of%20validation%20tailored%20to%20specific%20settings%20and%20challenges%20in%20tool%20development%2C%20was%20evident.%20We%20encourage%20applicants%20intending%20to%20use%20or%20develop%20novel%20PRO%2C%20ObsRO%20and%20PerfO%20tools%20that%20will%20generate%20evidence%20for%20regulatory%20submissions%20on%20medicines%20to%20consider%20Qualification%20procedures%20for%20novel%20methods%20to%20seek%20feedback%20on%20the%20development%20and%20validation%20of%20these%20tools.%22%2C%22date%22%3A%222023-09-11%22%2C%22language%22%3A%22en%22%2C%22DOI%22%3A%2210.1111%5C%2Fbcp.15907%22%2C%22ISSN%22%3A%221365-2125%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fonlinelibrary.wiley.com%5C%2Fdoi%5C%2Fabs%5C%2F10.1111%5C%2Fbcp.15907%22%2C%22collections%22%3A%5B%22YPQEBWCQ%22%5D%2C%22dateModified%22%3A%222024-02-23T12%3A40%3A55Z%22%7D%7D%2C%7B%22key%22%3A%228AZBTTLR%22%2C%22library%22%3A%7B%22id%22%3A5011%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Laverty%20and%20Meulien%22%2C%22parsedDate%22%3A%222019%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%3Cdiv%20class%3D%5C%22csl-bib-body%5C%22%20style%3D%5C%22line-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%5C%22%3E%5Cn%20%20%3Cdiv%20class%3D%5C%22csl-entry%5C%22%3ELaverty%2C%20Hugh%2C%20and%20Pierre%20Meulien.%202019.%20%26%23x201C%3BThe%20Innovative%20Medicines%20Initiative%20%26%23x2212%3B10%20Years%20of%20Public-Private%20Collaboration.%26%23x201D%3B%20%3Ci%3EFrontiers%20in%20Medicine%3C%5C%2Fi%3E%206.%20%3Ca%20class%3D%27zp-DOIURL%27%20href%3D%27https%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffmed.2019.00275%27%3Ehttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.3389%5C%2Ffmed.2019.00275%3C%5C%2Fa%3E.%3C%5C%2Fdiv%3E%5Cn%3C%5C%2Fdiv%3E%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20Innovative%20Medicines%20Initiative%20%5Cu221210%20Years%20of%20Public-Private%20Collaboration%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Hugh%22%2C%22lastName%22%3A%22Laverty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Pierre%22%2C%22lastName%22%3A%22Meulien%22%7D%5D%2C%22abstractNote%22%3A%22The%20Innovative%20Medicines%20Initiative%20%28IMI%29%20is%20a%20public-private%20partnership%20between%20the%20European%20Union%20and%20the%20European%20pharmaceutical%20industry.%20Born%20of%20the%20necessity%20to%20foster%20collaboration%20between%20different%20stakeholders%20in%20order%20to%20address%20growing%20challenges%20in%20bringing%20new%20medicines%20to%20market%20and%20the%20rapidly%20evolving%20healthcare%20landscape%2C%20IMI%20has%20successfully%20delivered%20the%20radical%20collaboration%20needed%20to%20address%20these%20challenges.%20In%20this%20article%20we%20reflect%20on%20some%20of%20the%20major%20achievements%20of%20the%20programme%20by%20highlighting%20a%20few%20of%20the%20key%20projects%20funded%20and%20the%20progress%20they%20have%20made%2C%20as%20well%20as%20some%20of%20the%20lessons%20learnt%20in%20delivering%20such%20an%20ambitious%20partnership.%20Those%20that%20drove%20the%20foundation%20of%20IMI%20recognized%20that%20to%20address%20these%20challenges%20required%20not%20just%20ambitious%20scientific%20approaches%2C%20but%20also%20an%20awareness%20of%20societal%20needs.%20Therefore%2C%20actors%20from%20beyond%20the%20traditional%20pharmaceutical%20research%20communities%20would%20be%20needed.%20One%20of%20the%20key%20successes%20of%20IMI%20has%20been%20to%20foster%20radical%20collaboration%20between%20diverse%20public%20and%20private%20partners%20of%20all%20types%2C%20including%20large%20pharmaceutical%20companies%2C%20SMEs%2C%20regulators%2C%20patient%20organizations%20and%20public%20research%20institutions.%20It%20has%20achieved%20this%20by%20being%20a%20neutral%20platform%20where%20all%20partners%20are%20bound%20by%20the%20same%20rights%20and%20responsibilities.%20Since%20it%20began%20there%20has%20been%20an%20evolution%20in%20the%20understanding%20of%20what%20is%20considered%20%5Cu201cpre-competitive%2C%5Cu201d%20resulting%20in%20IMI%20projects%20now%20addressing%20all%20of%20the%20steps%20within%20the%20pharmaceutical%20development%20value%20chain.%20With%20this%20expansion%20in%20the%20types%20of%20projects%20supported%20by%20IMI%2C%20different%20actors%20from%20beyond%20the%20traditional%20pharmaceutical%20research%20family%20have%20been%20attracted%20to%20participate%2C%20enriching%20further%20the%20collaboration%20at%20the%20heart%20of%20the%20programme.%20Finally%2C%20such%20a%20complex%20programme%20brings%20with%20it%20challenges%2C%20and%20we%20reflect%20on%20some%20of%20the%20important%20learnings%20that%20should%20be%20applied%20to%20future%20collaborative%20models%20to%20ensure%20that%20they%20are%20as%20successful%20as%20possible%20and%20deliver%20the%20expected%20impact.%22%2C%22date%22%3A%222019%22%2C%22language%22%3A%22%22%2C%22DOI%22%3A%2210.3389%5C%2Ffmed.2019.00275%22%2C%22ISSN%22%3A%222296-858X%22%2C%22url%22%3A%22https%3A%5C%2F%5C%2Fwww.frontiersin.org%5C%2Farticle%5C%2F10.3389%5C%2Ffmed.2019.00275%22%2C%22collections%22%3A%5B%22CK3S8BS5%22%5D%2C%22dateModified%22%3A%222022-09-02T16%3A17%3A43Z%22%7D%7D%5D%7D
Stephenson, Diane, Derek Hill, Jesse M. Cedarbaum, Maria Tome, Spiros Vamvakas, Klaus Romero, Daniela J. Conrado, et al. 2019. “The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease.” Journal of Parkinson’s Disease 9 (3): 553–63. https://doi.org/10.3233/JPD-191648.
Silva, Marcio, Jane Moseley, Thorsten Vetter, Jan Regnstrom, Maria Tome, Stiina Aarum, Francesca Cerreta, Elmer Schabel, and Spiros Vamvakas. 2023. “Patient-Reported, Observer-Reported and Performance Outcomes in Qualification Procedures at the European Medicines Agency (EMA) 2013-2018.” British Journal of Clinical Pharmacology 90 (1): 299–312. https://doi.org/10.1111/bcp.15907.
Laverty, Hugh, and Pierre Meulien. 2019. “The Innovative Medicines Initiative −10 Years of Public-Private Collaboration.” Frontiers in Medicine 6. https://doi.org/10.3389/fmed.2019.00275.